All posts by imreal

Oshi Health to Present Results of Virtual Multidisciplinary GI Care Clinical Trial at ATA 2023


Oshi Health logo

Oshi Health is virtual multidisciplinary digestive care

A recent clinical trial with a national payer that found that after six months of multidisciplinary telehealth care, 98% of patients were satisfied with their treatment and 92% achieved symptom improvement while achieving savings of $10,292 per patient.

oshihealth.com [Oshi Health __title__ Oshi Health], the virtual specialty care company transforming digestive health outcomes and economics, today announced that executives will be on hand at the American Telehealth Association’s 2023 Annual Conference & Expo as speakers and available to greet attendees at Booth 816-A in the IMPACT Pavilion in San Antonio, Texas on March 4-6, 2023.

Throughout the event Oshi Health will share its innovative approach to virtual multidisciplinary care in gastroenterology (GI), including:


  • Research Oral Presentation, Sunday, March 5 at 11:00 am CT: Dr. Sameer Berry, Oshi Health Chief Medical Officer, will share the findings of a recent clinical trial with a national payer that found that after six months of multidisciplinary telehealth care, 98% of patients were satisfied with their treatment and 92% achieved symptom improvement. Dr. Berry will lead attendees through data showing that study participants gained back an average of 1.3 work days per month while achieving savings of $10,292 per patient through avoidable imaging, reductions in unnecessary prescription drug use, and fewer emergency room visits.
  • AMA Future of Health Workshop, Sunday, March 5 at 1:00 pm CT: Dr. Berry will join this panel to discuss the future of digital medicine coding, coverage, and payment. As part of this plenary session, Dr. Berry will unpack how complex subspecialty virtual care can successfully interact with brick and mortar gastroenterologists through hybrid partnerships. Drawing on Oshi Health case studies, attendees will learn how collaboration through multi-channel engagement builds a virtuous cycle of care that benefits both patients and practices.
  • ATA 2023 Telehealth Innovators Challenge, Monday, March 6 at 5:00 pm CT: Sam Holliday, Oshi Health CEO,will take the stage to pitch Oshi’s clinically proven approach to GI care as a finalist in the 2023 Telehealth Innovators Challenge “In-Patient Care Solutions” category that spotlights digital solutions that help patients overcome access to care barriers. Attendees will learn how Oshi Health’s multidisciplinary digestive care model, which is grounded in whole-person care protocols that are clinically validated and recommended by the American College of Gastroenterology and American Gastroenterology Association, provides patients with convenient and high-touch virtual care, while lowering costs and improving patient satisfaction and symptom control.
  • Oshi Health Booth in the IMPACT Pavilion – Booth 816-A: Oshi Health team members will be available throughout the event in the IMPACT Pavilion. Conference goers are encouraged to stop by to learn more about how Oshi Health is transforming the digestive health experience through the power of telehealth and by partnering with innovative employers, health insurance partners, health systems, and community GI practices to bring multidisciplinary care to their populations.

About Oshi Health

Oshi Health is a completely redesigned digestive health care experience that transforms access to care, the patient experience, clinical outcomes and healthcare economics. In a high-touch virtual care delivery model, Oshi Health provides diagnosis and integrated care for digestive conditions and empowers people to achieve lasting control of their symptoms. Launched in 2020, Oshi Health works with innovative employers, health insurance partners, health systems and community GI practices to scale access to multidisciplinary care, reduce healthcare costs, and improve the lives of millions of Americans with chronic gastrointestinal diseases. For more information, visit http://www.oshihealth.com.

Share article on social media or email:

Global Veterinary Diagnostic Testing for Pets and Animals Will Grow to $5.8 Billion in 2027


“Diagnostic testing is an important aspect of animal healthcare. There is a wide variety of tests available for veterinarians to use to identify and monitor diseases.”

Where the pets go, so go the profits. This is true not just for mainstream pet products (such as food and toys) or services (such as grooming and boarding), but extends to veterinary pet healthcare, most notably veterinary diagnostic testing. Indeed, the global veterinary diagnostic market is forecast to grow to approximately $5.8 billion in 2027, according to The World Market for Veterinary Diagnostics, 6th Edition, the latest report by market research firm Kalorama Information.

The veterinary diagnostics market is best characterized preliminarily through its two primary segments: companion animal (pets such as dogs and cats and domestic animals including horses) and food animal (livestock and production animal) diagnostics. The two segments differ significantly in terms of demand, drivers and primary product groups. Infectious disease is a significant component in the veterinary care of companion animals, though improving standards and levels of consumer spending on companion animal care produce a much larger market for laboratory analyzers used for non-infectious disease or general health testing. Food animal diagnostics is led foremost by infectious disease assays in various forms described in this section.

“Diagnostic testing is an important aspect of animal healthcare. There is a wide variety of tests available for veterinarians to use to identify and monitor diseases,” says Bruce Carlson, publisher for Kalorama Information.

Veterinary diagnostic testing is becoming more mainstream as consumers embrace advanced pet healthcare. Diagnostic testing has become more sophisticated in the last several years benefiting from advancements in technology and accuracy. Testing has become a mainstay in the practice of veterinary medicine and has proven to be vital for the safety of food animals and well-being of companion animals. In vitro diagnostic (IVD) instrumentation and products have been extensively applied to veterinary healthcare; various assay forms, analytes and analyzers are transferrable from the clinical space to the veterinary clinic and laboratory.

Veterinary diagnostics comprehensively support animal health:


  • routine testing of companion animals during clinical visits or check-ups;
  • diagnosis of disease in symptomatic companion animals;
  • zoonotic disease surveillance in wildlife populations;
  • disease screening and confirmatory testing in livestock and production animals as part of disease control efforts.

International trade, public health, agricultural productivity, consumer confidence and companion animal-owner relationships are all dependent upon effective and increasingly specialized veterinary diagnostics products. Expertise in molecular diagnostics, virology and bacteriology is crucial in the food animal (livestock and production animal) diagnostics space as emergent threats and outbreaks necessitate the development and improvement of assays for newly implemented disease control programs. Technical barriers to entry in the lucrative companion animal diagnostics space are relatively low. Many market participants in companion animal diagnostics have adapted clinical diagnostic analyzers—hematology analyzers or blood counters, chemistry analyzers, critical care analyzers—with modifications limited mostly to reference ranges, sample preparation and some parameters.

PURCHASE THE REPORT

The World Market for Veterinary Diagnostics, 6th Edition examines the worldwide veterinary diagnostics market through the performance of its two component markets of companion animal (pets) and food animal diagnostics. The report provides analysis of major veterinary disease markets as well as overall market performance and development.

For more information or to purchase the market research report “The World Market for Veterinary Diagnostics, 6th Edition,” visit: https://kaloramainformation.com/product/veterinary-diagnostics-dogs-cats-horses-pets/.

ABOUT KALORAMA INFORMATION

Kalorama Information, part of Science and Medicine Group, is the leading publisher of market research in healthcare areas, including in vitro diagnostics (IVD), biotechnology, medical devices, and pharmaceuticals. Science and Medicine Group supports companies seeking to commercialize the rapidly changing marketplace at the intersection of science, medicine, and technology. Comprised of industry-leading brands, Science and Medicine Group serves analytical instrument, life science, imaging, and clinical diagnostic companies by helping them create strategies and products to win markets and provide platforms to digitally engage their markets through a variety of innovative solutions. Kalorama Information produces 30 reports a year. The firm offers a Knowledge Center, which provides access to all published reports.

Share article on social media or email:

Harm Reduction Specialist Training, Co-Created by Ken Vick, Benilde Hall Executive Director, is First State Credential to Roll Out Internationally


Benilde Hall Logo

Substance use is often a person’s coping mechanism for an underlying trauma, yet we treat the symptom (drug use) first, not the root cause of the using. Harm reduction flips treatment, addressing the causes first, such as depression or trauma, so the reason to abuse substances is gone.

A Harm Reduction credential offered by the Missouri Credentialing Board and based on training co-created by Ken Vick, Benilde Hall’s executive director, has been rolled out on the international level. This is the first time a Missouri-based credential has been offered internationally, validating and emphasizing the need to incorporate harm reduction services in treating substance use disorder.

Ken Vick explains, “We developed the Harm Reduction Certification specifically for professionals in Missouri, nationwide and internationally. As its creators, we developed this 21-hour-long certification to break stigmas associated with drug abuse and addiction. Harm reduction is a critical component of trauma-informed care, giving services needed and meeting people where they are, rather than activating them. Meaning substance use is often a person’s coping mechanism for an underlying trauma, yet we treat the symptom (drug use) first, not the root cause of the using. Harm reduction flips treatment, addressing the causes first, such as depression or trauma, so the reason to abuse substances is gone. Essentially, we as professionals need to treat the reasons for substance abuse and stop shutting down addicts’ coping mechanisms.”

The Harm Reduction credential also is in line with Health and Human Services’ Overdose Prevention Strategy. According to the Substance Abuse and Mental Health Services Administration (SAMHSA), the U.S. is experiencing the most significant substance use and overdose epidemic it has ever faced, exacerbated by a worldwide pandemic, and driven by the proliferation of highly potent synthetic opioids containing primarily fentanyl and other analogues.

Harm reduction is critical to keeping people who use drugs alive and as healthy as possible. Harm reduction services and training for professionals providing those services are needed now more than ever to help decrease overdose fatalities, acute life-threatening infections related to unsterile drug injection and chronic diseases such as HIV/HCV.

Objectives of the Missouri Credentialing Board’s Harm Reduction Certification:

  • Increase knowledge around Harm Reduction and how it can be used in recovery processes
  • Apply skills within a harm reduction framework to current practice
  • Feel comfortable having conversations around Harm Reduction with clients and the community
  • Identify obstacles in applying Harm Reduction and develop strategies to overcome these obstacles
  • Learn to engage people who are continuing to use substances into Harm Reduction recovery practices
  • Build the foundation for clinical and non-clinical communication around Harm Reduction strategies

The first Harm Reduction Certification training runs February 21-23, 2023 at Healing House in Kansas City, Missouri. The next training is scheduled for April 3-5, 2023 in St. Louis, Missouri. Professionals seeking to earn their Harm Reduction Certification can learn more or register on the Missouri Credentialing Board’s website.

###

About Ken Vick, Benilde Hall Executive Director

Kenneth “Ken” Vick’s difficult childhood led to substance use at a young age. A freshman high school dropout, he had his first felony at age 18. February 12, 2001 is the day he walked into prison and the last one he used drugs. Ken completed R-DAP (Residential Drug Abuse Program), starting his recovery journey and work in the recovery field. Ken put into practice what he’d learned at Benilde Hall as a practicum student, counselor-in-training, and eventually, senior counselor. He left Benilde Hall to become director of treatment services, clinical supervisor and program manager at other renowned centers. In 2019, Ken returned to Benilde Hall as executive director. To learn more about Ken Vick or Benilde Hall, visit http://www.benildehall.org.

Share article on social media or email:

GENH2 Partners with H2 GENESIS to Provide Small-Scale Hydrogen Liquefaction


“We are looking forward to working with our partners at H2 Genesis to begin our build-out in Florida and to expand nationwide and globally.” Greg Gosnell, President and CEO of GenH2

GenH2, an industry leader in hydrogen infrastructure solutions, today announced that the company has signed a partnership agreement with H2 Genesis, a leading liquid hydrogen infrastructure and operations company, to deliver liquid hydrogen across North America. In their first collaboration, GenH2, as manufacturer, and H2 Genesis, as owner-operator, will deploy the GenH2 LS20 Mobile Liquid Hydrogen System, an end-to-end liquefication and storage system, to several locations in the United States starting with Florida.

H2 Genesis, founded in 2021, is focused on proliferating access to the LH2 molecule for users of all sizes to advance the hydrogen economy. Through GenH2’s modular/flexible technology, the goal is to get liquid hydrogen in more hands than ever before and under a more near-term timeline that other technologies can provide. The first LH2 molecule is set to be delivered in 2023 with rapid expansion of the delivery network in subsequent years.

H2 Genesis focuses on asset development, hydrogen distribution, and infrastructure operations and service. Through the partnership with GenH2, H2 Genesis plans to facilitate the distributed hydrogen economy by developing over 1,600 MWdc of renewables power production and delivering of ~145,000 kg per day of liquid hydrogen by 2028.

“Hub development must provide access to all users, including those from traditionally marginalized communities or those with smaller yet important needs,” said Ben Frickel, Managing Director of H2 Genesis. “We seek to break down that bottleneck by providing researchers, innovators and industry with an effective supply of liquid hydrogen so that they can optimize the utility around this powerful molecule.”

The LS20 functions both as a stationary unit, or on a trailer for mobile use, which takes up significantly less space than most liquid hydrogen systems currently available. This mobile system will be the catalyst to developing a wide network of liquid hydrogen delivery. The units will enter the market in late 2023.

“We are looking forward to working with our partners at H2 Genesis to begin our build-out in Florida and to expand nationwide and globally,” added Greg Gosnell, President and CEO of GenH2. “Once deployed, these solutions will be an innovative addition to the options for advanced clean energy.”

As a complete system, the LS20 can liquefy, store, and dispense liquid hydrogen from any gaseous hydrogen source, such as a storage tank or an electrolyzer. The LS20 also serves as a foundation for higher capacity GenH2 systems including the 100Kg LH2 per day and 1,000Kg LH2 per day solutions.

“This is the first of its kind in advanced mobile liquefaction, storage, and delivery modules,” Frickel added. “The mobile system will be the catalyst for our company to form a wide network of liquid hydrogen delivery.”

About GenH2

GenH2 is a technology leader in hydrogen infrastructure systems for advanced clean energy. GenH2 solutions will allow for safe liquefaction, storage, and distribution of liquid hydrogen. The company will focus on mass-producing light-scale equipment to speed infrastructure buildout and make hydrogen accessible for everyday use around the globe. The Titusville, Florida-headquartered technology team includes former NASA researchers and developers who possess decades of experience researching, engineering, and building hydrogen solutions. Learn more about GenH2 at http://www.DiscoverHydrogen.com.

About H2 Genesis

H2 Genesis was formed in 2021 to be the leading liquid hydrogen infrastructure and service company in support of the hydrogen economy. We are a passionate group of engineers, scientists, developers and financial professionals with the goal of growing the hydrogen economy to the next level. For more information about H2 Genesis visit https://www.h2-genesis.com/.

Safe Harbor Statement

This release of communication possesses “forward-looking statements” in accordance with the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties about GenH2 and H2 Genesis, including but not limited to statements about: the expected benefits of the long-term strategic partnership between GenH2 and H2 Genesis; The expectation that GenH2’s partnership with H2 Genesis will strengthen its value chain and allow H2 Genesis to meet growing demand Liquid Hydrogen.

Share article on social media or email:

Cloudticity Recognized on CRN’s 2023 MSP 500 List in the Pioneer 250 Category


“We are honored to be recognized in the Pioneer 250 category and grateful that The Channel Company values Cloudticity’s genuine commitment as an MSP that strives to change the way healthcare interacts with people through our cost-optimizing, secure, and flexible, innovative solutions.”

Cloudticity, a cloud enablement partner for healthcare, announced today that CRN®, a brand of The Channel Company, has named Cloudticity to its Managed Service Provider (MSP) 500 list in the Pioneer 250 category for 2023. CRN’s annual MSP 500 list identifies the industry-leading service providers in North America who are driving a new wave of growth and innovation for the channel through forward-thinking approaches to managed services, helping end users increase efficiency and simplify IT solutions, while maximizing their return on investment.

MSPs have become a vital part of the success of businesses worldwide. MSPs not only empower organizations to leverage intricate technologies but also help them keep a strict focus on their core business goals without straining their budgets.

The annual MSP 500 list is divided into three sections: the MSP Pioneer 250, recognizing companies with business models weighted toward managed services and largely focused on the SMB market; the MSP Elite 150, recognizing large, data center-focused MSPs with a strong mix of on- and off-premises services; and the Managed Security 100, recognizing MSPs focused primarily on off-premises and cloud-based security services.

Cloudticity was chosen because of its comprehensive cloud-native security capabilities and unwavering embrace of the HITRUST CSF framework. HITRUST CSF is the gold standard for healthcare information security. It is the only framework that addresses the needs of a growing number of payers and providers and the only one that currently satisfies the Trusted Exchange Framework and Common Agreement (TEFCA) requirements for Qualified Health Information Networks (QHINs). Cloudticity security solutions enable HITRUST compliance and a faster path to certification.

“Managed services offer a path for businesses of all sizes to remain efficient and flexible as they grow,” said Blaine Raddon, CEO of The Channel Company. “The solution providers on our 2023 MSP 500 list are bringing innovative managed services portfolios to market, helping their customers win by doing more with the IT budgets they have and freeing up resources to focus on mission-critical activities to drive future success.”

“We are honored to be recognized in the Pioneer 250 category and grateful that The Channel Company values Cloudticity’s genuine commitment as an MSP that strives to change the way healthcare interacts with people through our cost-optimizing, secure, and flexible, innovative solutions.” – Gerry Miller, Founder & CEO, Cloudticity

The MSP 500 list will be featured in the February 2023 issue of CRN and online at http://www.crn.com/msp500.

About Cloudticity:

Cloudticity is a digital enablement partner for healthcare generating measurable business and clinical outcomes by unlocking the cloud’s full potential. Through advanced automation and deep cloud expertise, Cloudticity empowers healthcare organizations to create and scale next-gen healthcare solutions that are resilient and secure.

Cloudticity has built some of the first and largest health systems on the public cloud, including:

  • The first patient portal
  • The first health information exchange
  • The first FISMA high deployment
  • The first Meaningful Use 2 (MU2) compliance attestation for a large hospital system
  • The first Covid-19 registry for a state health department

Learn more at http://www.cloudticity.com

About The Channel Company

The Channel Company enables breakthrough IT channel performance with our dominant media, engaging events, expert consulting and education, and innovative marketing services and platforms. As the channel catalyst, we connect and empower technology suppliers, solution providers and end users. Backed by more than 30 years of unequalled channel experience, we draw from our deep knowledge to envision innovative new solutions for ever-evolving challenges in the technology marketplace. http://www.thechannelco.com

Follow The Channel Company: Twitter, LinkedIn, and Facebook.

© 2023 The Channel Company LLC. CRN is a registered trademark of The Channel Company, LLC. All rights reserved.

The Channel Company Contact:

Natalie Lewis

The Channel Company

nlewis@thechannelcompany.com

Share article on social media or email:



The Healthcare Innovation Company Announces Recent Additions to the Speaking Roster for Its Flagship Event, June 20-22, 2023, in Washington, D.C.


The Healthcare Innovation Company announced another wave of speakers for its second annual Healthcare Innovation Congress, thINc360, today.

The Healthcare Innovation Congress convenes senior leaders from across the healthcare ecosystem: Payers, Providers, Life Sciences organizations, government officials, start-ups, investors, and more. Taking place June 20-22 at the Grand Hyatt in Washington, D.C., thINc360 offers three days of content, including more than 150 speakers and 100 in-depth sessions spanning four comprehensive tracks.

“The Healthcare Innovation Congress brings healthcare leaders and organizations who are transforming healthcare to the forefront. We are extremely excited and honored to welcome these additional healthcare leaders to the program as a follow-up to our previously announced roster that includes, Dan Mendelson, Chief Executive Officer, Morgan Health; Lawrence Moss, MD, President and Chief Executive Officer, Nemours Children’s Health; and David Goldhill, Co-Founder and Chief Executive Officer, Sesame,” said Haritha Krishnarathnam, VP of Content and Strategy, thINc.

Recent additions the thINc360 faculty include:


  • Phoebe Yang, Fortune 2 Executive, Public and Private Company Board Director, Appointee in Two Presidential Administrations, Digital Transformation and Global Expansion Operator, Thought Leader, and Investor
  • LaShawn McIver, MD, MPH, Director, Centers for Medicare and Medicaid Services (CMS), Office of Minority Health (OMH)
  • Nancy Gin, MD, FACP, EVP, Quality, and Chief Quality Office, Kaiser Permanente
  • Caitlin Donovan, Global Head, Uber Health
  • Megan Adornato, Senior Vice President, Global Health Promotion Programs, Citi
  • Tim Engelhardt, Director, CMS Medicare-Medicaid Coordination Office, U.S. Centers for Medicare & Medicaid Services
  • Daniel Knecht, MD, MBA, VP and Chief Clinical Innovation Officer, CVS Caremark
  • Denise Basow, MD, MBA, EVP and Chief Digital Officer, Ochsner Health
  • Lisa Porter, Director of Community Engagement, Humana
  • Nwando Anyaoku, MD, MPH, MBA, VP, Chief Health Equity Officer, Providence North Division
  • Sanjay Desai, MD, Chief Academic Officer, Group VP of Medical Education, American Medical Association
  • Michelle Stansbury, VP, Innovation and IT Applications, Houston Methodist
  • U. Michael Currie, MPH, MBA, SVP and Chief Health Equity Office, UnitedHealth Group
  • Mirella Daja, VP, Future Business Strategy, Novo Nordisk
  • Rahul Kak, VP, Customer Health & Experience, CVS Health
  • Monte Masten, MD, MBA, MPH, Chief Medical Officer, Marsh McLennan Agency, LLC
  • Stuart Hart, MD, MBA, MS, FACOG, FACS, Chief Medical Officer, Integra LifeSciences
  • Neal Lemon, PhD, Executive Director, Cooper Innovation Center, Cooper University Health Care
  • Kathryn G. Schubert, MPP, CAE, President & CEO, Society for Women’s Health Research

Visit https://www.thinc360.com/2023event to view the full speaker line-up and register. Early registration rates are in effect and hotel rooms are filling up quickly for the Congress, so prospective attendees and sponsors are advised to act quickly.

About The Healthcare Innovation Congress (thINc360)

The Healthcare Innovation Congress, organized by The Healthcare Innovation Company, brings together two premier healthcare events – The World Health Congress for health plan, hospital system, government, and life sciences executives and Benefit Design Strategies for Employers (produced by Validation Institute) – together under one roof to form thINc360. Focused on delivering impactful content and creating meaningful connections, thINc360 gathers cross-sector healthcare leaders for the year’s most prominent industry event and offers a unique forum that inspires healthcare innovation. thINc360 takes place June 20-22, 2023, at the Grand Hyatt, Washington, D.C.

The Healthcare Innovation Company: https://thinc360.com

Validation Institute: https://validationinstitute.com

Share article on social media or email:

Innovative Health Presents Sustainability Awards to Hospitals Leading the Way in Responsible Device Use


It’s about more than financial savings. It’s about reducing the carbon footprint of hospitals and building a more sustainable supply chain for the future.

Innovative Health, Inc. today announced that the hospital recipients of its annual sustainability awards reduced their carbon emissions by an average of 7,219 pounds in 2022, while simultaneously saving an average of $544,662 on device costs. The recipients of the awards, which honor hospitals that have demonstrated their commitment to more-sustainable practices by leveraging reprocessed single-use devices in their EP and cath labs, represent leading hospitals that are rejecting common greenwashing tactics and are instead doubling down on the need to foster a circular economy in healthcare.

The importance of reprocessing programs as it relates to healthcare sustainability was recently highlighted in a report by the Agency for Healthcare Research & Quality, which specifically called out the problematic nature of designing products for single use: “Reliance on single-use disposable medical supplies and devices not only leaves health systems vulnerable to supply chain disruptions […], but they are frequently cited as containing higher life cycle emissions per use compared with equivalent application of reusable alternatives. Healthcare organizations should strongly encourage and facilitate resource stewardship.”

“Strong environmental and financial stewardship in healthcare today requires hospitals to build robust reprocessing programs,” said Innovative Health CEO Rick Ferreira. “As the recipients of Innovative Health’s sustainability awards illustrate, it’s about more than financial savings. It’s about reducing the carbon footprint of hospitals and building a more sustainable supply chain for the future.”

Innovative Health’s sustainability awards were presented to hospitals following a banner year for the medical device reprocessor. In addition to growing the number of hospitals that benefit from its reprocessing services by nearly 30 percent, Innovative Health grew savings for its customers by 20 percent in 2022. The number of clients saving more than $500,000 grew by 18 percent, with many realizing savings in excess of $1 million. Across the board, Innovative Health increased its CO2 emission reductions for clients by 15 percent year over year, representing a more than 280,000-pound carbon footprint reduction.

About Innovative Health

Innovative Health is an advanced medical device reprocessing company that offers smarter utilization of medical devices in hospitals’ cardiology and electrophysiology programs.

Share article on social media or email:

Removery Opens Flagship Location in The Flatiron District


News Image

“People change for a number of reasons. For whatever reason that is, we provide an opportunity for people to reflect on the outside who they are on the inside,” said Jo Kelton, COO of Removery.

Removery, the world’s tattoo removal experts, will open its flagship location in The Flatiron District on March 1st at 4 West 21st Street. At 2,604 square feet, this will be Removery’s largest location, with three treatment rooms and two consultation rooms.

In honor of its newest location, Removery will host a ceremonious first treatment with an individual who is currently in the company’s INK-nitiative program. Freddie, who was previously incarcerated, has tattoos covering his face, neck and head, and wanted the tattoos to be removed so he can reenter society without the marks of his past holding him back.

“I sometimes feel restrained when I have to go out in public because of the intimidating tattoos I have on my face,” said Freddie. “The removal will help me continue my path of redemption and reentry into society, tremendously improve my chances of getting a decent job and will lessen others’ judgement of me.”

Removery is providing the removal process for him free of charge to help him reach his goals. Over 300 clients are currently being treated through the INK-nitiative program at Removery.

Old tattoos can be a reminder of a past decision that no longer aligns with the present. Removery’s primary mission is to help people reflect on the outside, who they are on the inside. The technology used by Removery’s tattoo removal professionals allows clients to express themselves by completely removing a tattoo or fading just a small piece of it away, sometimes to make room for something new.

“People change for a number of reasons. For whatever reason that is, we provide an opportunity for people to reflect on the outside who they are on the inside,” said Jo Kelton, COO of Removery. “We want to empower people who have the desire to change and help them feel confident in their own skin.”

Removery’s Flatiron studio, located at 4 West 21st Street, New York, NY 10010, will host a special celebration from 9 a.m. to 11 a.m. on opening day, and regular business hours are 9:30 a.m. to 6 p.m. Tuesdays and Wednesdays, 10:30 a.m. to 7 p.m. Thursdays, 9 a.m. – 5:30 p.m. Fridays, and 9 a.m. to 2 p.m. on Saturdays.

For more information on Removery or to make an appointment, please call 866-602- 2561 or visit removery.com and connect with Removery on Instagram (@removery) or Facebook (@removery).

About Removery

Removery, the world’s tattoo removal experts, helps people reflect on the outside, who they are on the inside. Born from the partnership of North America’s four largest and most trusted tattoo removal brands, the company is committed to driving research and advancements in the world of laser tattoo removal while ensuring client safety and effective results. Removery is home to the world’s first tattoo removal Clinical Advisory Board dedicated to the advancement of the industry.

Removery’s research empowers our tattoo removal specialists to deliver the safest, most effective, and most accessible laser tattoo removal procedures using the state-of-the-art PicoWay® laser system by Candela. Currently, Removery has over 140 locations across the United States, Canada, and Australia and has performed 800,000+ treatments. The company’s goal is to normalize tattoo removal and empower clients to feel confident in their own skin.

For more information on Removery or to make an appointment, please call 866-602- 2561 or visit removery.com and connect with Removery on Instagram (@removery) or Facebook (@removery).

Share article on social media or email:



Bringing the Clinical Trials to the Patient, Upcoming Webinar Hosted by Xtalks


To fully realize the value of decentralization, remote patient centric sampling for laboratory pharmacokinetic, safety and biomarker measurements must be considered.

Patient burden associated with clinical trial participation continues to drive a gap between the number of trial patients needed and the number who give consent and participate. Trials typically require patient travel to hospitals or investigator sites, often 25 miles or more from the patient’s home. Decentralized and hybrid clinical trials aim to lessen patient burden by reducing practical barriers to trial participation thus improving patient access, recruitment and retention. Incorporating patient centric approaches can therefore be immensely beneficial.

To fully realize the value of decentralization, remote patient centric sampling for laboratory pharmacokinetic, safety and biomarker measurements must be considered. In this webinar, different approaches to bring sampling to the patient will be reviewed. The featured speakers will focus on innovative solutions in the pipeline and discuss considerations that must be taken into account when designing and validating a decentralized laboratory sampling approach.

Join this webinar to learn more about patient centric sampling and how decentralized and hybrid approaches bring clinical trials directly to the patient.

Join Stephanie Cape, PhD, Head of R&D, Scientific Affairs, Labcorp Drug Development; Bradley Collier, PhD, Research and Development Scientist, Labcorp; Satya N. Narla, PhD, NRCC(CC), Associate Director, Safety Testing Department, Labcorp Drug Development; Gregory Sommer, PhD, Technical Director, Research and Development, Labcorp, for the live webinar on Wednesday, March 15, 2023, at 11am EDT (4pm CET/EU-Central).

For more information, or to register for this event, visit Patient Centric Sampling: Bringing the Clinical Trials to the Patient.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Contact:

Vera Kovacevic

Tel: +1 (416) 977-6555 x371

Email: vkovacevic@xtalks.com

Share article on social media or email:

Pentec Health Inc., Will Be Featured on a Special Episode of “The Balancing Act®” Airing on Lifetime®


Pentec Health Inc., will be featured on a special episode of “The Balancing Act” airing on Lifetime® March 1st and March 8th at 7:30 a.m. in support of National Kidney Month. The episode will highlight the benefits of Proplete®, Intradialytic Parenteral Nutrition (IDPN), and Intraperitoneal Nutrition (IPN) protein therapies for malnourished hemodialysis and peritoneal dialysis patients. Dr. Amer Khan, a board-certified nephrologist and clinical hypertension specialist, will be joined by one of our patients who received Proplete® IDPN. Together, they will share insights about end stage renal disease, appropriate nutritional interventions, and personal experiences with Proplete® IDPN therapy, offered by Pentec Health, the nation’s leading provider of IDPN therapy.    

“Approximately 37 million adults in the United States have chronic kidney disease. If left untreated the disease can result in excess protein loss, malnutrition, and poor energy levels. In cases where patients are unable to optimize their protein intake adequately at home through their own diet or with oral supplements, nephrologists have the option of adding additional nutrition during dialysis treatments. One patented formulation on the market that I use for patients who need supplemental nutrition is Proplete® IDPN or IPN,” says Dr. Amer Khan, MD and board-certified nephrologist and clinical hypertension specialist. “Adding supplemental nutrition like Proplete® IDPN or IPN has many benefits such as improving the patient’s overall energy level, metabolism and appetite.”

Matthew Deans, Pentec Health’s Chief Strategy Officer and Executive Vice President, Clinical Nutrition Division, adds, “For 40 years, Pentec Health has been committed to improving the lives of malnourished hemodialysis and peritoneal dialysis patients through an empathetic approach focused on improving the quality of patient care. With “The Balancing Act,” our hope is that we create awareness and education for patients and caregivers on the benefits of IDPN and IPN therapy. This partnership creates a platform by which patients can discuss their options with their nephrologist and empowers them to advocate for their needs to determine if Proplete® IDPN or IPN is appropriate for them.”

For more information, please visit http://www.propletestrong.com

###

About Pentec Health

For 40 years, Pentec Health has been an industry leader in providing patient-specific compounded sterile medications. Pentec Health’s medications are used for administration in dialysis centers, as well as providing in-home Targeted Drug Delivery through nursing services and complex pharmaceutical products to patients who require access outside of a hospital setting. Pentec Health has built a tradition of exceptional patient care by committing to quality, safety, and innovation. We aim to be the provider of choice for sterile preparations and services in the healthcare marketplace. For more information, please visit http://www.pentechealth.com.

About The Balancing Act

The Balancing Act® is a morning show created and produced by BrandStar that offers sensible solutions and essential information in a fun, entertaining format; providing resources to help people do life better. The Balancing Act features everything from delicious recipes, style makeovers and dream getaways to parenting tips and the latest news in health and wealth. Tune in to The Balancing Act weekdays at 7:30 a.m. (ET/PT) on Lifetime®, and find all previously aired episodes on TheBalancingAct.com.

About BrandStar

We’re matchmakers; connecting People to Brands to Do Life Better. BrandStar has unparalleled experience in creating customized educational content for brands with laser targeted extensive distribution through their multi-channel network ecosystem and methodology. From Original television programming on Lifetime, BrandStar.tv, social media, digital marketing, to media management and PR; BrandStar helps brands connect with the right consumer, at the right time, with the right message, through all the right channels.

Share article on social media or email: